1. Medtech Insight
  2. >>Device Area
  3. >>Diabetic Care

Dexcom Shows Off More G7 Data

 
• By Barnaby Pickering

The newly published data solidifies the G7 as an improvement over the G6 and supports its potential as a 14-day wearable.

Dexcom G7
• Source: Alamy

Another set of data supporting the safety and accuracy of DexCom’s G7 continuous glucose monitor (CGM) is now published in Diabetes Technology & Therapeutics.

The 10-and-a-half day experiment included 316 participants with both type I and type II diabetes partake in in-clinic visits on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diabetic Care

Tariffs In Focus: Projections From 4 Medtech Giants (Q1 Vs Q2)

 
• By Marion Webb, Shubham Singh, and Nancy Pham

Roche Diagnostics, Intuitive Surgical, Abbott and Edwards Lifesciences all acknowledge tariff headwinds, but stress preparedness, resilience and mitigation. Below is look at how management framed the impact in Q1 vs Q2 earnings calls.

Dexcom Nabs Weight Management Indication For Signos CGM

 
• By Malcolm Spicer

Signos links users to Dexcom’s Stelo for glucose readings and historic trends. The app is available in iOS and Android from the firm’s website, where it’s priced at $139 for three-month plan and $129 for a two-month plan, or online app stores.

Medtronic Posts Solid First-Quarter, Adds Board Members As Elliott Takes Stake

 
• By Marion Webb

Medtronic beat first-quarter revenue and EPS estimates, raised guidance, and added two board members and special committees as Elliott takes a stake.

Luna Health Raises $23.6M, Furthering Launch Of ‘World’s Smallest’ Insulin Pump

 
• By Natasha Barrow

Luna Health has raised $23.6m in Series A funding to support regulatory submissions, clinical studies and manufacturing for its insulin patch pump.

More from Device Area

A Decade Of Breakthrough Devices: Cardiac And Orthopedic Products Dominate FDA Designations

 
• By Brian Bossetta and Elizabeth Orr

The US FDA has provided an update on its breakthrough devices program, now 10 years running. Cardiac, orthopedic, and neurological devices have received the most designations, while only one has been awarded to an obstetrics/gynecology product.

Terumo’s $1.5Bn Buyout Of OrganOx Vaults Company Into Organ Preservation Market

 
• By Marion Webb

Terumo will acquire OrganOx for about $1.5bn, adding the only FDA-cleared liver normothermic perfusion device to its portfolio. Analysts don’t expect the buyout to have a significant impact on competition, but the deal marks a strategic shift for Terumo into transplant medicine.

Dexcom Nabs Weight Management Indication For Signos CGM

 
• By Malcolm Spicer

Signos links users to Dexcom’s Stelo for glucose readings and historic trends. The app is available in iOS and Android from the firm’s website, where it’s priced at $139 for three-month plan and $129 for a two-month plan, or online app stores.